Proteome of a Moraxella catarrhalis Strain under Iron-Restricted Conditions

Luke V Blakeway1, Aimee Tan1, Ian R Peak1,2

  • 1Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia.

Insights

Moraxella catarrhalis

Area of Science:

  • Microbiology and Infectious Diseases
  • Proteomics
  • Bacterial Pathogenesis

Background:

  • Moraxella catarrhalis is a significant pathogen responsible for respiratory tract infections like otitis media and COPD exacerbations.
  • The bacterium's adaptation to iron-limited environments during infection is crucial for its survival and virulence but remains poorly understood.
  • Understanding iron metabolism is key to developing novel therapeutic strategies against M. catarrhalis.

Purpose of the Study:

  • To investigate the proteomic changes in Moraxella catarrhalis under iron-restricted conditions.
  • To identify specific proteins and pathways affected by iron starvation in M. catarrhalis.
  • To elucidate the role of iron availability in M. catarrhalis pathogenesis.

Main Methods:

  • Utilized sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) for comprehensive proteome analysis.
  • Compared the proteome of M. catarrhalis CCRI-195ME grown under iron-restricted versus iron-replete conditions.
  • Quantified differential protein expression to identify key adaptive responses.

Main Results:

  • Identified a significant number of differentially expressed proteins in M. catarrhalis upon iron restriction.
  • Observed alterations in pathways related to iron uptake, metabolism, and oxidative stress response.
  • Highlighted potential virulence factors affected by iron availability.

Conclusions:

  • Iron starvation significantly impacts the proteome of Moraxella catarrhalis, influencing its metabolic and virulence strategies.
  • The study provides a detailed proteomic map of M. catarrhalis' response to iron limitation.
  • Findings offer insights into bacterial iron acquisition mechanisms and potential therapeutic targets.